In addition to being one of the most important tissues in the body, blood has emerged as a key vector in the transmission of the world’s deadliest infectious diseases. With the rising demand for transfusions in a variety of conditions such as anemias, trauma, and high-blood-loss surgeries, supplies have been stretched and the dangers of disease transmission have added significant cost pressures to maintaining a safe supply.
One possible solution to ease the crunch, particularly in acute amergency care settings has been the development of synthetic blood substitutes and synthetic blood products. Blood products such as recombinant hemophilia factors and serum albumins are already on the market; oxygen carriers are only a few years away.
This briefing forecasts the market for synthetic blood products, including:
- Hemoglobin based oxygen carriers (HBOCs)
- Perflurocarbon based products (PFCs)
- Recombinant factors for hemophilias, such as Factor VIII (TKT)
- Synthetic platelets, and
- Blood volume expanders, such as the albumins.
Blood demand is detailed by number of high-blood-loss procedures, acute vs chronic conditions, and geographic region, and total demand is forecasted to 2009. Market share and revenues of top products in the blood volume expander and recombinant factor markets are reported and estimated out to 2009. Oxygen transporting product revenues are forecasted to 2013, based on likely approvals and clinical acceptance trends.
In addition, product pipelines are analyzed from both technical aspects and clinical trials results, and profiles of 11 key players are provided.